![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_123,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/SonomaEye-full-color-vector%5B2%5D.png)
Uveitis 2
Saturday, 3/22/2025
8:00 AM - 9:30 AM
Moderators: C. Michael Samson, MD, MBA and Stephen Anesi, MD
8:00 am – 8:05 am: Opening Remarks
8:05 am – 8:17 am: Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: A 52-Week Phase 2 Study (NEPTUNE). Stephen Anesi, MD
8:17 am – 8:29 am: Discontinuation of Adalimumab in JIA-associated Uveitis. Nisha Acharya, MD
8:29 am – 9:41 am: TPA: A (New) Tool in the Uveitis Armamentarium. Doran Spencer, MD, PhD
9:41 am – 9:53 am: An Open-Label, Multi-Centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability, and Bioactivity of Subcutaneous Repository Corticotropin Injection in Patients with Scleritis – The ATLAS Study: Preliminary Results. Chris Or, MD
9:53 am – 10:05 am: A Leaky Argument: Is Inflammation in IRD Uveitis? Nitish Mehta, MD
10:05 am – 10:17 am: An Update on Monitoring and Management of Birdshot Retinochoroidopathy. Peter Y. Chang, MD